MRC1 and myeloid sarcoma: The administration of ω-3 PUFAs to the CPZ-induced MS model (model for toxic demyelination) for 5 weeks exerted neuroprotective effects by alleviating demyelination and neurological deficits, downregulating M1-specific markers (CD16 and iNOS), and upregulating M2-specific markers (CD206, chitinase-like protein (Ym-1/2), and Arg1).